Medscint

🚀 We’re gearing up for another exciting meeting as the AAPM Spring Clinical Meeting kicks off this Saturday in Orlando, FL🌴

With two Orlando conferences in a row ( + ), Danahé and Francois are staying under the Florida 🌞 to showcase our 𝐇𝐘𝐏𝐄𝐑𝐒𝐂𝐈𝐍𝐓®𝐐𝐀 solutions at the American Association of Physicists in Medicine Spring Clinical Meeting.

Learn more about 𝐇𝐘𝐏𝐄𝐑𝐒𝐂𝐈𝐍𝐓®𝐐𝐀 ­❇️scintillation dosimetry solutions:
👉 https://medscint.com/products/hyperscint-qa/

Double the events ➜ double the opportunities to connect with the medical physics community, share insights, and highlight how our 𝐇𝐘𝐏𝐄𝐑𝐒𝐂𝐈𝐍𝐓®𝐐𝐀 technology supports:
✔️ Precision in 𖦏 𝐒𝐦𝐚𝐥𝐥‑𝐟𝐢𝐞𝐥𝐝 𝐃𝐨𝐬𝐢𝐦𝐞𝐭𝐫𝐲
✔️ Fast multi-target 𝐄𝐧𝐝‑𝐭𝐨‑𝐞𝐧𝐝, 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐚𝐧𝐝 𝐓𝐏𝐒 𝐐𝐀
✔️ Innovation in 𝐀𝐝𝐚𝐩𝐭𝐢𝐯𝐞 & 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐐𝐀 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬

Meet with our ⚛️ physics team onsite in Orlando:
👉 https://medscint.com/contact-medscint/

Safe travels ✈️ to everyone heading to these meetings, and wishing our team an inspiring and productive week ahead in the Sunshine State! 😎

Medscint

🎉 Exciting news from the 2025 AI Event ALL IN as Medscint and CHU de Québec-Université Laval become recipient of the💡INOVAIT Pilot Fund!

Represented at the event in Montreal by Pr. Louis Archambault, our collaborative project on the advent of 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝘁 𝗿𝗲𝗮𝗹-𝘁𝗶𝗺𝗲 𝗱𝗼𝘀𝗶𝗺𝗲𝘁𝗿𝘆 𝘁𝗼 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗲 𝗶𝗺𝗮𝗴𝗲-𝗴𝘂𝗶𝗱𝗲𝗱 𝗿𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗻𝗱 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘀𝗮𝗳𝗲𝘁𝘆 was recognized at 🍁Canada’s most important AI event. Our initiative highlights the transformative potential of Medscint ❇️scintillator's technology to advance the deployment of modern 🎗cancer care.

Led by Sunnybrook Health Sciences Centre Research Institute, INOVAIT's vision is to revolutionize healthcare by integrating artificial intelligence into image-guided therapy to enhance precision, safety, and patient outcomes.

This support reinforces our commitment to innovation in ⚛️medical physics, improving patient outcomes through smarter QA and data-driven radiotherapy solutions.

🔗 Learn more about INOVAIT Pilot Fund and selected projects: https://inovait.ca/inovait-announces-latest-pilot-fund-recipients-at-all-in-2025/

*****

🎉 Excellente nouvelle lors de l’événement dédié à l’IA - ALL IN 2025, alors que Medscint et le CHU de Québec - Université Laval deviennent récipiendaires du 💡INOVAIT Pilot Fund!

Représenté à Montréal par le Pr. Louis Archambault, notre projet collaboratif sur 𝗹'𝘂𝘁𝗶𝗹𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗱𝗲 𝗹𝗮 𝗱𝗼𝘀𝗶𝗺𝗲́𝘁𝗿𝗶𝗲 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝘁𝗲 𝗲𝗻 𝘁𝗲𝗺𝗽𝘀 𝗿𝗲́𝗲𝗹 𝗽𝗼𝘂𝗿 𝗼𝗽𝘁𝗶𝗺𝗶𝘀𝗲𝗿 𝗹𝗮 𝗿𝗮𝗱𝗶𝗼𝘁𝗵𝗲́𝗿𝗮𝗽𝗶𝗲 𝗴𝘂𝗶𝗱𝗲́𝗲 𝗽𝗮𝗿 𝗹’𝗶𝗺𝗮𝗴𝗲 𝗲𝘁 𝗮𝘀𝘀𝘂𝗿𝗲𝗿 𝗹𝗮 𝘀𝗲́𝗰𝘂𝗿𝗶𝘁𝗲́ 𝗱𝗲𝘀 𝘁𝗿𝗮𝗶𝘁𝗲𝗺𝗲𝗻𝘁𝘀 a été mis en lumière lors du plus grand événement 🍁canadien dédié à l'IA.

Notre initiative souligne le potentiel transformateur de la technologie à ❇️scintillation développée par Medscint pour faire progresser les soins contre le 🎗cancer.

Porté par l’Institut de recherche Sunnybrook, INOVAIT est un réseau pancanadien dont l’objectif est de créer un écosystème de thérapie guidée par imagerie véritablement intégré qui favorise l’innovation continue et révolutionne les soins de santé à l’échelle mondiale.

Ce soutien renforce notre engagement envers l’innovation en ⚛️physique médicale, avec pour objectif d’améliorer les résultats cliniques grâce à une assurance qualité plus intelligente et des solutions de radiothérapie basées sur les données.

🔗 En savoir plus sur le INOVAIT Pilot Fund et les projets sélectionnés :
https://inovait.ca/fr/inovait-annoncent-les-plus-recents-beneficiaires-du-fonds-pilote-a-loccasion-de-levenement-all-in-2025/

👏 Congratulations to all the selected teams | Félicitations à toutes les équipes sélectionnées:
Scopia Surgical, ViewsML, Reveal Surgical, Dova Health Intelligence, Vena Medical, Qalam Health Solutions, NZ Technologies, Light Matter Interaction Inc, A.I. VALI INC., NodeAI, Deep Breathe, Saentis, AI4Eyes, MetaOptima Technology Inc., iMIRGE and PragmaClin Research Inc.

🎉 Meet the new HYPERSCINT® QA at AAPM 2025 – The Next-Gen QA Clinical Tool for RT

After years of R&D and clinical collaboration, Medscint proudly introduces its new medical device HYPERSCINT® QA to the U.S. market!

📍 Visit our dynamic team onsite while you are in Washington DC to learn more.

About HYPERSCINT® QA :

✅ Boost confidence in small field dosimetry
✅ Streamline End-to-End QA
✅ Benefit from multi-point, real-time measurements

The HYPERSCINT® technology and solutions are already trusted by 50+ institutions worldwide. Learn more about our solutions for clinical and research applications by visiting our website 👇
https://medscint.com/products/hyperscint-qa/